Rallybio (RLYB) Competitors

Opus Genetics has a net margin of -892.36% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -55.79% beat Opus Genetics' return on equity.

Rallybio has higher earnings, but lower revenue than Opus Genetics. Rallybio is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

90.3% of Rallybio shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 10.3% of Rallybio shares are held by company insiders. Comparatively, 11.7% of Opus Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Rallybio has a beta of -0.89, suggesting that its share price is 189% less volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

Opus Genetics has a consensus price target of $10.83, indicating a potential upside of 166.18%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Opus Genetics is more favorable than Rallybio.

In the previous week, Opus Genetics had 7 more articles in the media than Rallybio. MarketBeat recorded 7 mentions for Opus Genetics and 0 mentions for Rallybio. Opus Genetics' average media sentiment score of 0.14 beat Rallybio's score of 0.00 indicating that Opus Genetics is being referred to more favorably in the news media.

In the previous week, Lexeo Therapeutics had 6 more articles in the media than Rallybio. MarketBeat recorded 6 mentions for Lexeo Therapeutics and 0 mentions for Rallybio. Lexeo Therapeutics' average media sentiment score of 0.60 beat Rallybio's score of 0.00 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

90.3% of Rallybio shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 10.3% of Rallybio shares are held by company insiders. Comparatively, 2.0% of Lexeo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lexeo Therapeutics has a consensus target price of $20.14, indicating a potential upside of 308.58%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Lexeo Therapeutics is more favorable than Rallybio.

Lexeo Therapeutics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Lexeo Therapeutics' return on equity of -47.48% beat Rallybio's return on equity.

Rallybio has a beta of -0.89, indicating that its share price is 189% less volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

Rallybio has higher revenue and earnings than Lexeo Therapeutics. Rallybio is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by insiders. Comparatively, 10.3% of Rallybio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Larimar Therapeutics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -55.79% beat Larimar Therapeutics' return on equity.

Rallybio has higher revenue and earnings than Larimar Therapeutics. Rallybio is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Larimar Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Rallybio has a beta of -0.89, meaning that its share price is 189% less volatile than the broader market.

Larimar Therapeutics presently has a consensus target price of $15.29, suggesting a potential upside of 320.17%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Larimar Therapeutics is more favorable than Rallybio.

In the previous week, Larimar Therapeutics had 1 more articles in the media than Rallybio. MarketBeat recorded 1 mentions for Larimar Therapeutics and 0 mentions for Rallybio. Larimar Therapeutics' average media sentiment score of 0.00 equaled Rallybio'saverage media sentiment score.

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Comparatively, 10.3% of Rallybio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Enanta Pharmaceuticals has a net margin of -89.56% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -55.79% beat Enanta Pharmaceuticals' return on equity.

Rallybio has lower revenue, but higher earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

Enanta Pharmaceuticals has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Rallybio has a beta of -0.89, meaning that its stock price is 189% less volatile than the broader market.

Enanta Pharmaceuticals presently has a consensus target price of $20.29, indicating a potential upside of 60.23%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Enanta Pharmaceuticals is more favorable than Rallybio.

In the previous week, Enanta Pharmaceuticals had 1 more articles in the media than Rallybio. MarketBeat recorded 1 mentions for Enanta Pharmaceuticals and 0 mentions for Rallybio. Enanta Pharmaceuticals' average media sentiment score of 0.00 equaled Rallybio'saverage media sentiment score.